U.S. FDA Granted Priority Review to Dizal's Sunvozertinib New Drug Application
If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with EGFR exon20ins Sunvozertinib's NDA was submitted based on the multinational pivotal WU-KONG1 Part B...
![Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma](http://prnewswire.vietreader.com/thumb/190x300/2025-01/norgine-submits-marketing-authorisation-application-to-the-european-medicines-agency-for-eflornithine-difluoromethylornithine-dfmo-in-high-risk-neuroblastoma-1.jpg)
Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
Back to media releases Next media release LONDON, Jan. 7, 2025 /PRNewswire/ -- Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma...
Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration
SAN FRANCISCO and SUZHOU, China, Jan. 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...
IND Application for a Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Approved
SUZHOU, China, Dec. 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific...
Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis
CHENGDU, China, Dec. 23, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of...
Jianpu Technology Inc. Extends Its Share Repurchase Program
BEIJING, Dec. 23, 2024 /PRNewswire/ -- Jianpu Technology Inc. ("Jianpu," or the "Company") (OTCQB: AIJTY), a leading open financial technology platform in China, today announced that its board of directors (the "Board") has approved an extension of...
Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration
SAN FRANCISCO and SUZHOU, China, Dec. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...
Macao breaks new ground in practice of "one country, two systems"
BEIJING, Dec. 18, 2024 /PRNewswire/ -- A report from People's Daily: Over the past 25 years since Macao's return to China, the practice of "one country, two systems" with Macao characteristics has achieved remarkable success, thanks to the Chinese...
Global Times: Macao Science-1 a successful example of 'one country, two systems' advantage
BEIJING, Dec. 17, 2024 /PRNewswire/ -- The successful launch of Macao Science-1 satellites, the first space science satellite program jointly developed by the Chinese mainland and Macao, owes much to the strong support of scientists and engineers...
Thailand BOI Approves 10.5 Billion Baht Investment by Foxsemicon Integrated Technology's Subsidiary to Make High-Precision Machinery Parts and Equipment for Semiconductor Sector
BANGKOK, Dec. 11, 2024 /PRNewswire/ -- The Thailand Board of Investment (BOI) today announced it has granted investment privileges to a 10.5 billion baht (ca. US$ 306 million) investment by UNIQUE Integrated Technology Co., Ltd., a subsidiary of...